Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
This study is currently recruiting participants.
Verified October 2010 by University of Pittsburgh

First Received on October 14, 2010.  
No Changes Posted
Sponsor: University of Pittsburgh
Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: University of Pittsburgh Identifier: NCT01222273

The purpose of this study is to see if giving people with CF and ABPA enough vitamin D to make their blood levels of the vitamin higher, will reduce the allergic response in their body and make the symptoms caused by ABPA better.

Condition Intervention Phase
Cystic Fibrosis
Allergic Bronchopulmonary Aspergillosis
A. Fumigatus
Dietary Supplement: cholecalciferol (Vitamin D3) Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:

  • Aspergillus induced IL-13 responses in CD4+ T-cells [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To test the hypothesis that supplementation with Vitamin D in CF patients with ABPA will reduce Aspergillus induced IL-13 responses in CD4+ T-cells.

Secondary Outcome Measures:

  • Total IgE, Aspergillus specific IgE and IgG levels, vitamin D levels, FEV1, cytokine production by Aspergillus stimulated peripheral blood T cells, urine calcium/creatinine ratio [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    To test the hypothesis that supplementation with Vitamin D in CF patients with ABPA will reduce total and aspergillus specific IgE levels

Estimated Enrollment: 15
Study Start Date: September 2010
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Intervention Details:

    Dietary Supplement: cholecalciferol (Vitamin D3)

    4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months

Detailed Description:

Many patients with cystic fibrosis (CF) cough up mucus or have throat cultures that grow a common fungus called Aspergillus. In patients with CF, aspergillus is not known to cause direct damage to the lungs, but some patients respond with an allergic reaction that causes them to wheeze, cough, or have difficulty breathing. This allergic reaction is called ABPA. Current treatment for ABPA includes high dose steroids and an "anti-fungal" medicine. Treatment with steroids may be problematic for some people due to its side effects on blood sugar levels and the bones. Steroids are medications that decrease inflammation, including prednisone, medrol, dexamethasone and others.

Ongoing research at UPMC on the study "Mechanisms of Immune Tolerance in ABPA" has studied people with CF and ABPA versus those patients with CF that just grow A. fumigatus (Af) in the sputum, but do not have ABPA. You may have participated in this study. This study has shown that people with CF with the fungus, Af, in their sputum but who do not have ABPA have more of a certain type of cell in their blood that helps the body to regulate or suppress allergic reactions than those people with CF and ABPA.

Recent studies have demonstrated that Vitamin D is a critical factor in the development of these cells that suppress allergic reactions. People with CF, due to their pancreatic insufficiency that causes them to have difficulty absorbing fat, also have lower levels of the fat soluble vitamins which include vitamin D. In the study done at UPMC, "Mechanisms of Immune Tolerance in ABPA", people with CF and ABPA had significantly lower vitamin D levels than people with CF who did not have ABPA.


Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female ≥ 12 years of age at enrollment
  2. Confirmed diagnosis of CF based on the following criteria:

    1. One or more clinical features consistent with the CF phenotype AND (b or c)
    2. Positive sweat chloride > 60 mEq/liter (by pilocarpine iontophoresis)
    3. two identifiable mutations consistent with CF
  3. Written informed consent (and assent when applicable) obtained from subject or subject’s legal representative and ability for subject to comply with the requirements of the study.
  4. Clinically stable at enrollment as assessed by the site investigator
  5. Past or present respiratory culture positive for Aspergillus fumigatus
  6. IgE ≥ 250 and/or presence of class II or higher aspergillus specific IgE on enrollment
  7. Ability to comply with medication use, study visits and study procedures as judged by the site investigator –

Exclusion Criteria:

  • 1. Systemic corticosteroids (1 mg/kg if < 20 kg or > 20 mg of prednisone per day),.

    2. Investigational drug use within 30 days of screening 3. Laboratory abnormalities at screening

    a. Serum Calcium > 11 mg/dl b. 25(OH) D > 50 ng/ml at screening. c. Creatinine ≥ 1.5, or estimated GFR <60 by Cockcroft-Gault or MDRD equation. d. LFT≥ 3xULN

    4. History of transplantation or currently on lung transplant list 5. Positive serum pregnancy test at screening (to be performed on all post-menarche females) 6. Pregnant, breastfeeding, or if post-menarche female, unwilling to practice birth control during participation in the study 7. Presence of a condition or abnormality that in the opinion of the site investigator would compromise the safety of the subject or the quality of the data 8. Diagnosis of HIV and a CD4+ T cell count below 500 cells/ml or active hepatitis B or C infection.

    9. Undergoing therapy for non-tuberculous mycobacterial infection

  Contacts and Locations

Please refer to this study by its identifier: NCT01222273

Contact: Elizabeth Hartigan, MPH, RN, CRM 412-692-7060
Contact: Adrienne DeRicco, BSN, RN 412-692-8069

United States, Pennsylvania
Children’s Hospital of Pittsburgh of UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Principal Investigator: Joseph M Pilewski, MD            
Comprehensive Lung Center – Falk Clinic Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Principal Investigator: Joseph M Pilewski, MD            
Sponsors and Collaborators
University of Pittsburgh
Principal Investigator: Joseph M Pilewski, MD University of Pittsburgh
Study Director: Jay K Kolls, MD Louisiana State University Health Sciences Center in New Orleans
  More Information

No publications provided

Responsible Party: Joseph M. Pilewski, MD, University of Pittsburgh Identifier: NCT01222273    
History of Changes
Other Study ID Numbers: PRO09090370, 7P50HL084932-04
Study First Received: October 14, 2010
Last Updated: October 14, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:

cystic fibrosis
Allergic bronchopulmonary aspergillosis
A. fumigatus
Immune response

Additional relevant MeSH terms:

Aspergillosis, Allergic Bronchopulmonary
Cystic Fibrosis
Pulmonary Aspergillosis
Lung Diseases, Fungal
Lung Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Respiratory Tract Infections
Hypersensitivity, Immediate
Immune System Diseases
Pancreatic Diseases
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes
Vitamin D
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Bone Density Conservation Agents processed this record on August 21, 2012

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>




4 × 2 =